Background. Solitary dermal melanoma (SDM) is confined to the dermal and/or subcutaneous tissue without an epidermal component. It is unclear whether this lesion is a subtype of primary melanoma or distant cutaneous metastasis from an unknown primary. We evaluated our large experience to determine the prognosis and optimal management of SDM. Methods. Our melanoma referral center's database of prospectively acquired records was used for identification and clinicopathologic analysis of patients presenting with SDM between 1971 and 2005. Results. Of 12,817 database patients seen during a 34-year period, 101 (0.8%) had SDM. Of 92 patients free of distant metastasis on initial presentation, 55 (60%) were observed and 37 (40%) underwent surgical nodal staging: regional metastases were identified in 7 (19%). Nodal recurrence occurred in 1 of 30 patients (3.3%) with histopathologynegative nodes compared with 13 of 55 patients (24%) who underwent nodal observation instead of nodal staging. Thus, 21 of 92 patients (23%) had nodal metastasis identified during surgical nodal staging or postoperative nodal observation. At a median follow-up of 68 months, estimated 5-year overall survival rate was 73% for 71 patients with localized disease versus 67% for 21 patients with regional disease (P = 0.25) versus 22% for 9 patients with distant disease (P = 0.009, regional versus distant disease). Conclusions. SDM resembles intermediate-thickness primary cutaneous melanoma with respect to prognostic characteristics and clinical evolution, but its rate of distant metastasis justifies radiographic staging and its high rate of regional node metastasis justifies wide excision and sentinel node biopsy.
Melanoma without a known epidermal primary may present clinically in various forms, including metastatic melanoma with palpable lymphadenopathy involving single or multiple sites, or a solitary dermal lesion. Solitary dermal melanoma (SDM) is confined to the dermis and/or subcutaneous tissue without an epidermal component and is without other physical evidence of melanoma. SDM is infrequently reported in literature with an incidence between 0.4% and 0.9% (Table 1) . [1] [2] [3] [4] [5] [6] Because of this infrequency, the prognostic significance of SDM is unclear. Some have found this entity to be similar to stage IV metastatic disease (M1a) or in transit metastases (N2c) from an unknown primary, portending a poor overall prognosis, 1, 5 whereas others report survival rates exceeding 80%, [2] [3] [4] 7 pointing to a regressed primary melanoma or a distinct entity called a primary dermal melanoma.
The rarity, uncertain etiology, and unclear prognostic implications of SDM have discouraged a standardized approach to its evaluation and management. Although sentinel node biopsy (SNB) and radiographic studies are routine for evaluation of localized melanoma and distant melanoma, respectively, their role for evaluation of SDM is less certain. SNB is a standard staging and management technique for primary cutaneous melanoma and is useful for isolated local and in-transit recurrent melanoma from a known primary. [8] [9] [10] If SDM represents a form of localized/ early-stage melanoma or in-transit disease, then SNB may prove to be useful in detecting microscopic nodal metastasis. However, if the clinical outcome of SDM indicates a later stage melanoma, then radiographic evaluation would be essential to detect distant disease not evident on physical examination. We reviewed our large experience with melanoma to evaluate the incidence and prognosis of SDM and define management recommendations for these patients.
PATIENTS AND METHODS
The extensive computerized melanoma database at the John Wayne Cancer Institute (JWCI) was queried to identify all patients with SDM between January 1971 and December 2005. SDM was diagnosed by histologic evidence of a single focus of melanoma, which was limited to dermal and/or subcutaneous tissue, had no epidermal component, was not associated with a known synchronous or prior primary, and was not associated with evidence of regional/distant disease on physical examination.
At JWCI, all patients with apparent SDM undergo a thorough examination, including cutaneous evaluation to search for a potential primary source, and radiographic studies, including brain and body imaging to search for distant metastases. The histologic diagnosis of SDM is established by excisional biopsy, or confirmed by wide excision after a suspicious result on fine-needle aspiration (FNA). Shave biopsy is not appropriate for SDM because the lesion has no dermal/epidermal component. If there is no radiographic evidence of distant disease, treatment involves wide excision of SDM. Nodal evaluation with SNB (or elective complete lymphadenectomy [CLND] in the pre-SNB era) usually is undertaken at the time of wide excision but never more than 3 months after initial diagnosis. Patients with sentinel node (SN) metastasis undergo CLND. If preoperative radiographic staging reveals distant metastases, management options include systemic therapy and/or metastasectomy.
For this study, each patient's age, sex, site of SDM, extent of disease, diagnostic procedure, treatment procedure, and clinical outcome were retrieved by database and chart review. Although pathology reports were reviewed as necessary to confirm SDM, the slides and original tissue were not available in all cases. Also, because the rarity and appearance of SDM often suggest a metastatic rather than a primary tumor, histopathologic characteristics of this lesion were not consistently evaluated and therefore are not considered in our study.
The follow-up period was the interval between diagnosis of SDM and either death due to any cause or last follow-up. For patients without distant disease, time to nodal progression was measured from the date of wide excision and/ or lymphadenectomy. For all patients, overall survival was defined as the interval between surgical treatment of SDM and death due to any cause or censored at last follow-up. Survival rates and median survival times were derived from the Kaplan-Meier method and compared by log-rank test. Significant covariates (P \ 0.05) on survival were identified by multivariate analysis using Cox regression. Statistical analysis was performed using SAS software (SAS Institute Inc., Cary, NC).
Approval for this retrospective study was obtained from the institutional review board of the John Wayne Cancer Institute at Saint John's Health Center.
RESULTS
The clinical information for 12,817 patients with melanoma was prospectively registered during the study period. Among the more than 900 patients with an unknown primary melanoma, 101 presented with SDM (Table 2) . Most patients were younger than 60 years (69%) and male (62%). Both the mean age and median age were 52 (range, 21-84) years. The most frequent site for SDM was the extremity (42%). Mean and median follow-up periods were 7.3 and 5.6 years, respectively (range, 0.4-34.5 years). Staging evaluation of 101 SDM patients revealed localized melanoma in 85 patients (84%), regional melanoma in 7 patients (7%), and distant melanoma in 9 patients (9%). Of 92 patients (91%) with local or regional disease, 37 (40%) underwent nodal staging by SNB or elective CLND, and 55 (60%) underwent nodal observation without nodal staging (Fig. 1) . No specific features were used to triage patients to lymphadenectomy or observation; often the decision reflected patient preference after a discussion of treatment options and associated risks/benefits. Of 37 patients assessed by nodal staging, 20 (54%) underwent SNB (3 with positive SNs and 17 with negative SNs), whereas 17 (46%) were managed by elective CLND (4 with positive nodes and 13 with negative nodes). Thus, seven patients had histopathology-positive nodes (4 in axilla, 1 in neck, 2 in groin). The mean number of tumorpositive nodes was 1.4 (median, 1; range, 1-3). All seven patients with tumor-positive SNs underwent CLND. Nodal recurrence occurred in 1 of 30 patients (3.3%) with histopathology-negative nodes.
Of 55 patients who underwent nodal observation, 13 (24%) developed nodal recurrence. All 13 patients had palpable nodal metastases in the drainage basin predicted by the anatomic site of the SDM; this basin was invariably the same as that predicted for a known primary melanoma at the same site. Mean time to nodal progression was 21.5 (median, 15.2; range, 4.3-72.2) months. Tumor-involved nodes were identified in three neck basins, four axillary basins, five inguinal basins, and one interpectoral basin. The number of removed nodes ranged from 1 to 44, and three patients had only a single node removed. In 12 patients with nodal metastasis, the mean number of positive nodes was 2 (median, 1; range, 1-6). Complete nodal data were not available for the remaining patient, who was treated with CLND and subsequent radiation therapy.
In summary, 21 of 92 patients (23%) with local/regional disease had nodal metastasis at the time of nodal staging or developed nodal metastasis during nodal observation.
Of the 101 patients, the 9 with distant disease had metastases in the brain (2 patients), lung (2 patients), or multiple sites (5 patients). Initial treatment for metastatic disease included single therapy with interleukin (1 patient), radiation (1 patient), vaccine (1 patient), chemotherapy (1 patient), biochemotherapy (1 patient), or a combination of immunotherapy and cytokines (2 patients). Treatment information was not available for 2 patients.
Median survival and 5-year overall survival rate for the 101 patients were 8.3 years and 66%, respectively. Because 14 of 92 patients developed nodal progression that might have been due to missed nodal disease, survival was analyzed by combining this group with the seven node-positive patients. Overall survival was not significantly different for 71 patients with localized disease versus 21 patients with regional disease (P = 0.25), but it was significantly different for 21 patients with regional disease versus 9 patients with distant disease (P = 0.009; Fig. 2) . Of the 71 patients with localized disease, those younger than 60 years had significantly better survival (Table 3) . Sex, site of SDM, and decade of diagnosis were not significant. Age was the only variable that was prognostically significant by multivariate analysis (P = 0.039; hazard ratio, 2.140; 95% CI, 1.038-4.415). 
DISCUSSION
Our study, the largest yet reported on SDM, confirms the low (\1%) incidence of SDM in the melanoma population and the generally favorable survival after wide excision of SDM in patients without distant metastasis. However, the infrequency of this clinical entity has made appropriate and extensive analyses difficult and prognostic significance unclear in previous studies. Further, few studies have been dedicated to SDM (Table 1) . Most reports on SDM are intermixed with analyses that involve unknown primary melanoma, and specific demographic information is not available or not evaluated.
1,4-7 Reported single-center series are small, precluding adequate comparisons, and analysis of patient-related and lesion-related variables is spotty and inconsistent. 2, 3 Thus, SDM has yet to be linked to a higher-risk age group, sex, or anatomic site.
Most of our patients were younger than 60 years and most were male, consistent with previous studies of unknown primary melanoma and population-based studies. [11] [12] [13] [14] This trend might simply reflect the distribution of Like other demographic information, data on common sites of SDM involvement are inconsistent or not available in previous studies. [1] [2] [3] [4] [5] [6] [7] 16 Most of our patients had SDM on an extremity. Larger studies on primary cutaneous melanoma have shown a more favorable outcome with the extremity site compared with trunk and head/neck sites.
14,17 However, we found no site-related differences that might explain the generally more favorable survival of our SDM population (Table 3) .
Common explanations for SDM include (1) distant subcutaneous metastasis (M1a) or regional in-transit metastasis (N2c) from a primary that underwent complete regression, (2) primary dermal melanoma (PDM), or (3) primary melanoma with regressed epidermal component. The first explanation portends the poorest outcome with reported 5-year OS rates of 19% for an M1a lesion and 12-42% for an N2c lesion in patients with a known primary melanoma. [18] [19] [20] Similarly, some have reported a 5-year survival rate of 25% and median survival of 28 months for solitary subcutaneous lesions in patients without a known primary. 1, 5 These survival rates are too low to support metastasis from an unknown primary as an explanation for SDM in our study group.
A more feasible explanation for SDM is a PDM or primary melanoma with regressed epidermal component. Contrary to the poorer outcomes expected for M1a and N2c lesions, reported 5-year survival rates for localized primary melanoma with an epidermal component are 45-95% depending on the thickness and presence of ulceration. 18 Several small studies evaluated the thickness of resected nonulcerated SDM lesions; mean Breslow thickness was approximately 6-7 mm, a depth characteristic of a thick primary melanoma, but the lower range of thickness included 1-2 mm, a depth characteristic of intermediatethickness melanoma. 2, 3 Although these studies and others 4, 7 were too small for statistically meaningful analysis of survival, their reported outcomes were more similar to those for nonulcerated intermediate and thick primary melanomas (5-year OS rates 67-89%) than to those for metastatic disease (Table 1) . 18 It is less clear whether SDM represents PDM or an epidermally regressed primary. Swetter et al. described PDM as a unique subtype of melanoma, which may be biologically less aggressive than primary melanoma of similar Breslow thickness and associated with prolonged survival. 2 In their follow-up immunohistochemical study, Cassarino et al. reported that PDM could be distinguished from primary nodular melanoma and cutaneous metastatic melanoma by significant differences in the IHC staining of several antigens. 16 Some have speculated that a primary dermal melanoma may arise from nonepidermal melanocytes or intradermal nevi. 3 However, none of these studies reported evidence of a preexisting residual nevus. Also, the introduction of selection bias for this specific entity may have affected the results in such studies. 2, 3 Others have demonstrated a regression phenomenon of the epidermal component evidenced by a lymphocytic infiltrate. 21 An immune-mediated process may confine the tumor locally, and the passage of time might eliminate detectable evidence of regression with a lymphocytic infiltrate. In our study, the staging of SDM yielded three prognostic groups based on extent of disease. The prognosis for patients with localized disease (5-year survival of 73%) was similar to that described in other studies of SDM [2] [3] [4] 7 and similar to that associated with intermediate or thick primary melanomas. Prognosis for patients with nodal involvement (5-year survival of 67%) matched or exceeded that for patients presenting with regional node metastasis from a known primary melanoma. Importantly, 23% of patients presenting with an SDM had evidence of nodal involvement or later developed nodal disease. Of those not staged by nodal evaluation, 24% had disease that progressed to regional nodes. Hence, microscopic nodal disease may have been detected if nodal evaluation had been performed on original diagnosis of SDM. Such a high percentage of nodal involvement is not unexpected, because the predicted occurrence of microscopic nodal metastasis correlates directly with tumor Breslow thickness. 22, 23 Hence, this is a strong indication for routine use of SNB as a staging and management tool. [8] [9] [10] As expected, prognosis was least favorable (5-year survival of 22%) when the staging workup revealed distant metastasis (9%). Staging evaluation was essential to identify this cohort of patients for appropriate stage-related treatment.
Like the smaller studies of SDM, our study is subject to the selection bias inherent in a retrospective search. 2, 3 However, even if a future prospective analysis lowers the estimated survival rates, our findings allow specific recommendations for staging and management of patients presenting with clinical and histologic evidence of a solitary subcutaneous melanoma without an epidermal component. These patients require thorough evaluation with attention to the history and dermatologic examination, and a full metastatic survey, including imaging studies. Evaluation of the maximum tumor diameter in the vertical plane may be a more accurate prognostic indicator than traditional Breslow thickness, because the overlying epidermal thickness could vary from one anatomical site to another. 2 If there is no clinical or radiographic evidence of metastatic disease, the regional nodes should be assessed with SNB because approximately 23% of SDM patients will harbor nodal metastasis.
CONCLUSIONS
Patients with SDM have survival characteristics not unlike those associated with intermediate or thick primary melanoma, and therefore should undergo wide excision and regional staging with SNB. Because patients with regional nodal metastasis from SDM have a prognosis similar to that for patients with regional nodal metastasis from a known primary melanoma, they should be managed for regional rather than distant disease.
